まとめ
口服避妊薬と血栓栓塞栓症に関する科学的研究の質は,報告された発生率に大きく影響を与えます. より質の高い研究は,より大きなリスクを示し,現在の低発生率の発見に異議を唱えます.
科学分野:
- 医学研究方法論 医学研究方法論
- 医薬品監視 医薬品監視
- エピデミオロジー エピデミオロジー
背景:
- 経口避妊薬と血栓塞栓性エピソードの関係については,遡及的および前向きのデータを調査した研究によって議論されてきた.
- Drill and Calhounなどの以前の分析では,これらのイベントの発生率に関する結論を裏付けるために,さまざまな記事を引用しました.
研究 の 目的:
- 口服避妊薬と血栓栓塞栓症の議論で引用された研究の科学的メリットを批判的に評価する.
- 科学的証拠の質が,報告された血栓塞栓性エピソードの発生率に影響を与えるかどうかを評価する.
主な方法:
- 口服避妊薬と血栓栓塞栓症に関する議論で以前に引用された科学的論文のレビューと再評価.
- 血栓塞栓問題に関する科学的功績に基づいて選択された記事のランキング.
- 研究の質,報告された血栓塞栓症発生率,サンプルサイズとの相関性の分析.
主要な成果:
- 引用された多くの記事には,研究報告の厳しさが欠け,一部は一般的な,定量的なコメントのみを提供しました.
- 科学的な質によってランク付けされたとき,より高いメリットを持つ研究は,より高い血栓栓塞栓症の発生率を報告しました.
- 質の高い研究も,より少ない被験者を対象とする傾向がありました.
結論:
- トロンボエボリックエピソードの報告された全般的な発生率は,サンプルサイズが大きい,より厳格な研究が含まれているため,過小評価されている可能性があります.
- 経口避妊薬のリスクに関する現在の評価には,潜在的なバイアスが存在し,より質の高い科学的証拠に基づいた再評価が必要である.
関連する概念動画
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...